Biotech: Page
-
Apogee eczema drugs gets Blackstone backing, heads to Phase 3
The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.
By Kristin Jensen • May 27, 2026 -
News roundup
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
By Ben Fidler • May 26, 2026 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Q&A // China competition
SR One’s Simeon George on how China is rewriting biotech’s venture playbook
The veteran investor says that the trove of ready-made prospects is making the global biotech ecosystem “more competitive” and steering dollars away from “half-baked ideas.”
By Gwendolyn Wu • May 26, 2026 -
Parkinson’s drug from Biogen, Denali comes up short
High-level results have led the companies to scrap a mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.
By Jacob Bell • Updated May 22, 2026 -
RA Capital banks $75M for a biotech SPAC
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.
By Gwendolyn Wu • May 21, 2026 -
BioMarin notches win in study that could expand use of top-selling medicine
The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition.
By Kristin Jensen • May 21, 2026 -
IPO window
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.
By Jonathan Gardner • May 20, 2026 -
Startup launches
Oorja, run by Acceleron veterans, launches to make new fibrosis drugs
The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.
By Gwendolyn Wu • May 20, 2026 -
News roundup
Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.
By BioPharma Dive staff • May 20, 2026 -
BioMarin drug acquired in buyout misses goal in rare disease study
Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.
By Delilah Alvarado • May 19, 2026 -
A migraine drugmaker heads to the public markets through reverse merger
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.
By Jacob Bell • May 19, 2026 -
Relay drug shows early promise against rare blood vessel diseases
While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.
By Ben Fidler • May 19, 2026 -
News roundup
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.
By BioPharma Dive staff • May 18, 2026 -
Regeneron immunotherapy combo comes up short in melanoma trial
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.
By Ben Fidler • May 18, 2026 -
FDA hold puts Aardvark Prader-Willi drug in limbo
The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.
By Jonathan Gardner • May 15, 2026 -
News roundup
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted immune drug.
By BioPharma Dive staff • May 15, 2026 -
Create Medicines raises $122M to bolster in vivo CAR-T therapies
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
By Delilah Alvarado • May 14, 2026 -
News roundup
Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B
Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.
By BioPharma Dive staff • May 13, 2026 -
Deep Dive // Pain drugs
A year after Vertex’s big launch, pain drug research faces a pivotal moment
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
By Jacob Bell • May 12, 2026 -
News roundup
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.
By Ben Fidler • May 11, 2026 -
Biotech layoffs are easing, but is the worst over?
BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.
By Kelly Bilodeau • May 11, 2026 -
News roundup
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.
By Ben Fidler • May 8, 2026 -
IPO window
Odyssey, on second try, snags $279M in an IPO
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concurrent private deal.
By Gwendolyn Wu • May 7, 2026 -
Angelini to buy Catalyst in $4B play for rare neuro drugs
The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.
By Gwendolyn Wu • May 7, 2026 -
Entrada shares dive as Duchenne results disappoint
While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares subsequently tumbled more than 50%.
By Kristin Jensen • May 7, 2026